These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38854928)

  • 1. Review of Opioid Abuse-Deterrent Formulations: Impact and Barriers to Access.
    Webster L; Gudin J
    J Pain Res; 2024; 17():1989-2000. PubMed ID: 38854928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza ER.
    Geoffrey Severtson S; Kreider SED; Amioka EC; Margolin ZR; Iwanicki JL; Dart RC
    Pain Med; 2020 Dec; 21(12):3660-3668. PubMed ID: 33094329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxycodone DETERx
    Gudin J
    Pain Ther; 2016 Dec; 5(2):171-186. PubMed ID: 27873179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Abuse Deterrent Formulations of Opioids in Patients With Chronic Pain in the United States: A Cost-Effectiveness Model.
    Kumar VM; Agboola F; Synnott PG; Segel C; Webb M; Ollendorf DA; Banken R; Chapman RH
    Value Health; 2019 Apr; 22(4):416-422. PubMed ID: 30975392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of abuse-deterrent opioids and recommendations for practical patient care.
    Adler JA; Mallick-Searle T
    J Multidiscip Healthc; 2018; 11():323-332. PubMed ID: 30026658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abuse-deterrent opioids: an update on current approaches and considerations.
    Pergolizzi JV; Raffa RB; Taylor R; Vacalis S
    Curr Med Res Opin; 2018 Apr; 34(4):711-723. PubMed ID: 29262730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.
    Gudin J; Levy-Cooperman N; Kopecky EA; Fleming AB
    Pain Med; 2015 Nov; 16(11):2142-51. PubMed ID: 26108255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of physical manipulation on the oral pharmacokinetic profile of Xtampza
    Gudin J
    J Opioid Manag; 2020; 16(2):127-139. PubMed ID: 32329888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and future development of extended-release, abuse-deterrent opioid formulations in the United States.
    Webster LR; Markman J; Cone EJ; Niebler G
    Postgrad Med; 2017 Jan; 129(1):102-110. PubMed ID: 27915497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Formulary Coverage and Use of Abuse-Deterrent Prescription Opioids, Risk for Abuse or Overdose, and Associated Healthcare Resource Utilization.
    Petrilla A; Marrett E; Shen X; Kwong WJ; Pezalla E
    Am Health Drug Benefits; 2020 Feb; 13(1):21-31. PubMed ID: 32165996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitigation of IV Abuse Through the Use of Abuse-Deterrent Opioid Formulations: An Overview of Current Technologies.
    Rauck RL
    Pain Pract; 2019 Apr; 19(4):443-454. PubMed ID: 30597739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abuse of immediate-release opioids and current approaches to reduce misuse, abuse and diversion.
    Nalamachu SR; Shah B
    Postgrad Med; 2022 May; 134(4):388-394. PubMed ID: 30025214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the durability of pain relief throughout a 12 hour dosing interval of a novel, extended-release, abuse-deterrent formulation of oxycodone.
    Nalamachu S; Kopecky EA; Taylor R; Vaughn B; O'Connor M
    Curr Med Res Opin; 2016 Jul; 32(7):1311-7. PubMed ID: 27025986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A US Retrospective Claims Analysis Comparing Healthcare Costs of Patients Transitioning from Immediate-Release Oxycodone to Two Different Formulations of Extended-Release Oxycodone: Xtampza ER or OxyContin.
    Olatoke O; Zah V; Stanicic F; Vukicevic D; Yfantopoulos P; Thompson C; DeGeorge MK; Passik S
    Clinicoecon Outcomes Res; 2022; 14():119-128. PubMed ID: 35264862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abuse-Deterrent Opioid Formulations and the Opioid Crisis: A Pharmacist's Perspective.
    Gadd S; Cox N; Samuelson J; Kenney A; Turner K; Cochran G
    Ther Drug Monit; 2021 Feb; 43(1):35-41. PubMed ID: 33278243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A tale of 2 ADFs: differences in the effectiveness of abuse-deterrent formulations of oxymorphone and oxycodone extended-release drugs.
    Cicero TJ; Ellis MS; Kasper ZA
    Pain; 2016 Jun; 157(6):1232-1238. PubMed ID: 27186712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and impact of prescription opioid abuse deterrent formulation technologies.
    Alexander L; Mannion RO; Weingarten B; Fanelli RJ; Stiles GL
    Drug Alcohol Depend; 2014 May; 138():1-6. PubMed ID: 24613631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
    Cicero TJ; Ellis MS
    JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population.
    Jewell J; Black J; Ellis M; Olsen H; Iwanicki J; Dart R
    Clin Drug Investig; 2023 Mar; 43(3):197-203. PubMed ID: 36859697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in severity of poison centers exposures involving XTAMPZA
    Severtson SG; Haanschoten EE; Iwanicki J; Dart RC
    Pain Manag; 2023 Sep; 13(9):519-527. PubMed ID: 37850331
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.